-
Notifications
You must be signed in to change notification settings - Fork 1
/
acr-appropriateness-criteria--abdominal-aortic-aneurysm-interventional-planning-and-followup
1394 lines (1272 loc) · 143 KB
/
acr-appropriateness-criteria--abdominal-aortic-aneurysm-interventional-planning-and-followup
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app16.us.archive.org';v.server_ms=198;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />
<!-- End Wayback Rewrite JS Include -->
<title>ACR Appropriateness Criteria&reg; abdominal aortic aneurysm: interventional planning and follow-up. | National Guideline Clearinghouse</title>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width">
<link rel="icon" href="/web/20180712210119im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
<link rel="apple-touch-icon" sizes="180x180" href="/web/20180712210119im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
<link rel="icon" type="image/png" href="/web/20180712210119im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
<link rel="icon" type="image/png" href="/web/20180712210119im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
<link rel="manifest" href="/web/20180712210119/https://www.guideline.gov/UI/images/manifest-NGC.json">
<link rel="mask-icon" href="/web/20180712210119im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
<meta name="theme-color" content="#ffffff">
<link href="/web/20180712210119cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->
<script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180712210119js_/https://dap.digitalgov.gov/Universal-Federated-Analytics-Min.js?agency=HHS&subagency=AHRQ"></script>
</head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain ECH-1199-->
<!-- Google Tag Manager -->
<noscript>
<iframe src="//web.archive.org/web/20180712210119if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
</noscript>
<script>
(function (w, d, s, l, i) {
w[l] = w[l] || []; w[l].push({
'gtm.start':
new Date().getTime(), event: 'gtm.js'
}); var f = d.getElementsByTagName(s)[0],
j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
'//web.archive.org/web/20180712210119/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
})(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>
<noscript>
<iframe src="//web.archive.org/web/20180712210119if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
</noscript>
<script>
(function (w, d, s, l, i) {
w[l] = w[l] || []; w[l].push({
'gtm.start':
new Date().getTime(), event: 'gtm.js'
}); var f = d.getElementsByTagName(s)[0],
j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
'//web.archive.org/web/20180712210119/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
})(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
<!-- End Google Tag Manager -->
<!-- AHRQ HEADER -->
<div id="ahrq-header">
<p class="hhs-links">
<a href="https://web.archive.org/web/20180712210119/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S. Department of Health and Human Services</a>
<a href="https://web.archive.org/web/20180712210119/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
</p><!-- /.hhs-links -->
<p class="ahrq-links">
<a href="https://web.archive.org/web/20180712210119/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
<a href="https://web.archive.org/web/20180712210119/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
</p><!-- /.ahrq-links -->
</div><!-- /#ahrq-header -->
<!-- HEADER -->
<div class="header" id="header">
<div class="masthead">
<ul class="header-actions">
<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
</ul><!-- /.header-actions -->
<a href="/web/20180712210119/https://www.guideline.gov/" class="header-logo NGC">
<picture>
<source media="(min-width: 960px)" srcset="/web/20180712210119im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
<source srcset="/web/20180712210119im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
<img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
</picture>
</a>
<form action="/web/20180712210119/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get"> <p class="search-bar">
<label for="q"><span class="screen-reader-text">Search</span>
<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
</label>
<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
</p>
<p class="search-tips">
<a href="/web/20180712210119/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
</p>
</form> <div class="header-account header-action" id="header-account">
<a id="login-button" class="signin" href="/web/20180712210119/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
<div class="sign-in">
<form id="sign-in-form" action="/web/20180712210119/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
<h3>Sign In</h3>
<div class="errormessages"></div>
<p class="invalid-user-cred message-block" style="display: none;"></p>
<p>
<label for="sign-in-username">Username or Email <span class="required">*</span></label>
<input type="text" id="sign-in-username" class="input-text" name="email" required>
</p>
<p>
<label for="sign-in-userpwd">Password <span class="required">*</span></label>
<input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
</p>
<p class="form-link"><a href="/web/20180712210119/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
<p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
<input id="account-sign-in" type="submit" value="Sign In"/>
</form>
<p>
<label for="sign-up-btn">Don't have an account?</label>
<a href="/web/20180712210119/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
</p>
</div><!--/.sign-in-->
</div><!-- /.login -->
</div><!-- /.header-account -->
</div><!-- /.masthead -->
<div class="main-nav header-action" id="main-nav">
<ul class="level-1">
<li class=""><a href="/web/20180712210119/https://www.guideline.gov/">Home</a></li>
<li class=""><a href="/web/20180712210119/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
<li>
<a href="/web/20180712210119/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a> <ul class="level-2 dropdown">
<li class=""><a href="/web/20180712210119/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
<li class=""><a href="/web/20180712210119/https://www.guideline.gov/browse/organization">By Organization</a></li>
<li class=""><a href="/web/20180712210119/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
<li class=""><a href="/web/20180712210119/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
<li class=""><a href="/web/20180712210119/https://www.guideline.gov/summaries/archive">Archive</a></li>
<li class=""><a href="/web/20180712210119/https://www.guideline.gov/search?f_DocType=0&fLockTerm=Guideline Summaries">All Summaries</a></li>
</ul>
</li>
<li class=""><a href="/web/20180712210119/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li> <li class=""><a href="/web/20180712210119/https://www.guideline.gov/expert">Expert Commentaries</a></li>
<li class=""><a href="/web/20180712210119/https://www.guideline.gov/matrix">Matrix Tool</a></li>
<li class="">
<a href="/web/20180712210119/https://www.guideline.gov/summaries/submit">Submit Guidelines</a> </li>
<li class=""><a href="/web/20180712210119/https://www.guideline.gov/help-and-about">Help & About</a></li>
</ul>
</div><!-- /.main-nav -->
</div><!-- /.header -->
<br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180712210119/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>
<!-- CONTENT -->
<main id="main-content" tabindex="-1">
<div class="main">
<div class="aside-container">
<div class="content">
<!-- CONTENT HEADER -->
<div class="content-header">
<ul class="content-header-meta">
<li class="prefix-icon guideline">Guideline Summary</li>
<li>NGC:011330</li>
<li>2017
</li>
<li>
<div class="flag-box"><span class="neats"></span> NEATS Assessment</div>
<a class="icon-info" href="/web/20180712210119/https://www.guideline.gov/help-and-about/summaries/determining-extent-adherence-to-the-iom-standards-in-ngc"><span class="screen-reader-text">Learn More About NEATS Assessment</span></a>
</li>
</ul>
<div>
<h1>ACR Appropriateness Criteria® abdominal aortic aneurysm: interventional planning and follow-up.</h1>
</div>
</div>
<!-- /.content-header-meta -->
<!-- CONTENT TABS -->
<ul class="content-tabs">
<li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
<li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
<li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
<li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
<li><a href="#neats-tab" class="NEATS"><span class="label">NEATS Assessment</span></a></li> </ul>
<div id="developer-tab" class="is-active content-tab-panel">
<ul class="developer-list">
<li><a href="/web/20180712210119/https://www.guideline.gov/search?f_Guideline_Developer_String=American%20College%20of%20Radiology&fLockTerm=American%2BCollege%2Bof%2BRadiology">American College of Radiology</a></li>
<li>
<a id="246" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
</li>
</ul>
</div>
<!-- /.content-tab-panel -->
<div id="source-tab" class="content-tab-panel">
<table><tr><td>Francois CJ, Skulborstad EP, Majdalany BS, Chandra A, Collins JD, Farsad K, Gerhard-Herman MD, Gornik HL, Kendi AT, Khaja MS, Lee MH, Sutphin PD, Kapoor BS, Kalva SP, Expert Panels on Vascular Imaging and Interventional Radiology. ACR Appropriateness Criteria® abdominal aortic aneurysm: interventional planning and follow-up. Reston (VA): American College of Radiology (ACR); 2017. 13 p. [100 references]</td></tr></table> <p><a href="/web/20180712210119/https://www.guideline.gov/Home/Disclaimer?id=51252&contentType=fulltextlink&redirect=https%253a%252f%252facsearch.acr.org%252fdocs%252f70548%252fNarrative%252f">View the original guideline documentation</a> <img alt="External Web Site Policy" src="/web/20180712210119im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
</div>
<!-- /.content-tab-panel -->
<div id="status-tab" class="content-tab-panel">
<p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Francois CJ, Kramer JH, Rybicki FJ, Ray CE Jr, Bandyk DF, Burke CT, Dill KE, Gerhard-Herman MD, Hanley M, Hohenwalter EJ, Mohler ER III, Rochon PJ, Schenker MP, Expert Panel on Vascular Imaging and Interventional Radiology. ACR Appropriateness Criteria® abdominal aortic aneurysm: interventional planning and follow-up. [online publication]. Reston (VA): American College of Radiology (ACR); 2012. 8 p. [71 references]</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div></p>
</div>
<!-- /.content-tab-panel -->
<div id="classification-tab" class="content-tab-panel">
<h4>UMLS Concepts <a href="/web/20180712210119/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
<div class="field">
<h5 class="field-label">ICD9CM</h5>
<div class="field-content">
<a href="/web/20180712210119/https://www.guideline.gov/search?f_ICD9CM_CUI=C0265011&fLockTerm=Abdominal+aneurysm+without+mention+of+rupture">Abdominal aneurysm without mention of rupture</a>
(441.4), <a href="/web/20180712210119/https://www.guideline.gov/search?f_ICD9CM_CUI=C0340629&fLockTerm=Aortic+aneurysm+of+unspecified+site+without+mention+of+rupture">Aortic aneurysm of unspecified site without mention of rupture</a>
(441.9), <a href="/web/20180712210119/https://www.guideline.gov/search?f_ICD9CM_CUI=C0003515&fLockTerm=Aortography">Aortography</a>
(88.42), <a href="/web/20180712210119/https://www.guideline.gov/search?f_ICD9CM_CUI=C0011923&fLockTerm=Diagnostic+imaging%2c+not+elsewhere+classified">Diagnostic imaging, not elsewhere classified</a>
(88.90) </div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">MSH</h5>
<div class="field-content">
<a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0002978&fLockTerm=Angiography">Angiography</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0003486&fLockTerm=Aortic+Aneurysm">Aortic Aneurysm</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0162871&fLockTerm=Aortic+Aneurysm%2c+Abdominal">Aortic Aneurysm, Abdominal</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0003515&fLockTerm=Aortography">Aortography</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C1536105&fLockTerm=Computed+Tomography+Angiography">Computed Tomography Angiography</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0009924&fLockTerm=Contrast+Media">Contrast Media</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0011923&fLockTerm=Diagnostic+Imaging">Diagnostic Imaging</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0243032&fLockTerm=Magnetic+Resonance+Angiography">Magnetic Resonance Angiography</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0030678&fLockTerm=Patient+Care+Planning">Patient Care Planning</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C1962945&fLockTerm=Radiography">Radiography</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0034573&fLockTerm=Radiography%2c+Abdominal">Radiography, Abdominal</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0936234&fLockTerm=Tomography+Scanners%2c+X-Ray+Computed">Tomography Scanners, X-Ray Computed</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0040405&fLockTerm=Tomography%2c+X-Ray+Computed">Tomography, X-Ray Computed</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0041618&fLockTerm=Ultrasonography">Ultrasonography</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MSH_CUI=C0242845&fLockTerm=Ultrasonography%2c+Doppler%2c+Duplex">Ultrasonography, Doppler, Duplex</a>
</div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">MTH</h5>
<div class="field-content">
<a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C0002978&fLockTerm=angiogram">angiogram</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C0003486&fLockTerm=Aortic+Aneurysm">Aortic Aneurysm</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C0340629&fLockTerm=Aortic+aneurysm+without+mention+of+rupture+NOS">Aortic aneurysm without mention of rupture NOS</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C0162871&fLockTerm=Aortic+Aneurysm%2c+Abdominal">Aortic Aneurysm, Abdominal</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C0936234&fLockTerm=Computed+Tomography+Scanning+Systems">Computed Tomography Scanning Systems</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C0009924&fLockTerm=Contrast+Media">Contrast Media</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C0011923&fLockTerm=Diagnostic+Imaging">Diagnostic Imaging</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C1522577&fLockTerm=follow-up">follow-up</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C0243032&fLockTerm=Magnetic+Resonance+Angiography">Magnetic Resonance Angiography</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C1962945&fLockTerm=Radiographic+imaging+procedure">Radiographic imaging procedure</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C0034573&fLockTerm=Radiography%2c+Abdominal">Radiography, Abdominal</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C0041618&fLockTerm=Ultrasonography">Ultrasonography</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_MTH_CUI=C0040405&fLockTerm=X-Ray+Computed+Tomography">X-Ray Computed Tomography</a>
</div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">PDQ</h5>
<div class="field-content">
<a href="/web/20180712210119/https://www.guideline.gov/search?f_PDQ_CUI=C0002978&fLockTerm=angiography">angiography</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_PDQ_CUI=C0040405&fLockTerm=computed+tomography">computed tomography</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_PDQ_CUI=C0011923&fLockTerm=diagnostic+imaging">diagnostic imaging</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_PDQ_CUI=C0041618&fLockTerm=ultrasonography">ultrasonography</a>
</div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">SNOMEDCT_US</h5>
<div class="field-content">
<a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0162871&fLockTerm=Abdominal+aortic+aneurysm">Abdominal aortic aneurysm</a>
(233985008), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0265011&fLockTerm=Abdominal+aortic+aneurysm+without+rupture">Abdominal aortic aneurysm without rupture</a>
(75878002), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0412254&fLockTerm=Abdominal+aortogram">Abdominal aortogram</a>
(168941001), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0002978&fLockTerm=Angiography">Angiography</a>
(77343006), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003486&fLockTerm=Aortic+aneurysm">Aortic aneurysm</a>
(67362008), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003515&fLockTerm=Aortography">Aortography</a>
(54640009), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040405&fLockTerm=Computerized+axial+tomography">Computerized axial tomography</a>
(77477000), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009924&fLockTerm=Contrast+media">Contrast media</a>
(385420005), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009924&fLockTerm=Contrast+media">Contrast media</a>
(407935004), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1536105&fLockTerm=CT+angiography">CT angiography</a>
(418272005), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0034573&fLockTerm=Diagnostic+radiography+of+abdomen">Diagnostic radiography of abdomen</a>
(60654006), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0242845&fLockTerm=Duplex+ultrasound">Duplex ultrasound</a>
(312236008), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0011923&fLockTerm=Imaging">Imaging</a>
(363679005), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0243032&fLockTerm=Magnetic+resonance+imaging+(MRI)+of+vessels">Magnetic resonance imaging (MRI) of vessels</a>
(241663008), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0336660&fLockTerm=Magnetic+resonance+imaging+unit">Magnetic resonance imaging unit</a>
(90003000), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1962945&fLockTerm=Radiographic+imaging+procedure">Radiographic imaging procedure</a>
(363680008), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0041618&fLockTerm=Ultrasonography">Ultrasonography</a>
(16310003), <a href="/web/20180712210119/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0041618&fLockTerm=Ultrasonography">Ultrasonography</a>
(278292003) </div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">SPN</h5>
<div class="field-content">
<a href="/web/20180712210119/https://www.guideline.gov/search?f_SPN_CUI=C0302622&fLockTerm=SYSTEM%2c+IMAGING%2c+PULSED+DOPPLER%2c+ULTRASONIC">SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_SPN_CUI=C0336660&fLockTerm=SYSTEM%2c+NUCLEAR+MAGNETIC+RESONANCE+IMAGING">SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING</a>
, <a href="/web/20180712210119/https://www.guideline.gov/search?f_SPN_CUI=C0936234&fLockTerm=SYSTEM%2c+X-RAY%2c+TOMOGRAPHY%2c+COMPUTED">SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED</a>
</div>
<!-- /.field-content -->
</div>
<!-- /.field -->
<div class="field">
<h5 class="field-label">UMD</h5>
<div class="field-content">
<a href="/web/20180712210119/https://www.guideline.gov/search?f_UMD_CUI=C0009924&fLockTerm=Contrast+Media">Contrast Media</a>
(16-573), <a href="/web/20180712210119/https://www.guideline.gov/search?f_UMD_CUI=C0492899&fLockTerm=Radiographic+Systems">Radiographic Systems</a>
(18-429), <a href="/web/20180712210119/https://www.guideline.gov/search?f_UMD_CUI=C0936234&fLockTerm=Scanning+Systems%2c+Computed+Tomography">Scanning Systems, Computed Tomography</a>
(13-469), <a href="/web/20180712210119/https://www.guideline.gov/search?f_UMD_CUI=C0336660&fLockTerm=Scanning+Systems%2c+Magnetic+Resonance+Imaging">Scanning Systems, Magnetic Resonance Imaging</a>
(16-260), <a href="/web/20180712210119/https://www.guideline.gov/search?f_UMD_CUI=C0302622&fLockTerm=Scanning+Systems%2c+Ultrasonic">Scanning Systems, Ultrasonic</a>
(14-278) </div>
<!-- /.field-content -->
</div>
<!-- /.field -->
</div>
<!-- /.content-tab-panel -->
<div id="neats-tab" class="content-tab-panel">
<p id="NeatsDescription">
National Guideline Clearinghouse (NGC) has assessed this guideline's adherence to standards of trustworthiness, derived from the Institute of Medicine's report
<a href="/web/20180712210119/https://www.guideline.gov/disclaimer?id=51252&contentType=summary&redirect=http%3A%2F%2Fnationalacademies.org%2Fhmd%2FReports%2F2011%2FClinical-Practice-Guidelines-We-Can-Trust.aspx"><i>Clinical Practice Guidelines We Can Trust</i></a> <img alt="External Web Site Policy" src="/web/20180712210119im_/https://www.guideline.gov/UI/images/icon_externallink.gif">.
</p>
<div class="ratings" aria-hidden="true">
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-1.png" alt="Poor"/> = Poor</span>
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-2.png" alt="Fair"/> = Fair</span>
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-3.png" alt="Good"/> = Good</span>
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-4.png" alt="Very Good"/> = Very Good</span>
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-5.png" alt="Excellent"/> = Excellent</span>
</div>
<table aria-describedby="NeatsDescription">
<thead>
<tr>
<th id="section">NEATS Assessment <a class="icon-info" href="/web/20180712210119/https://www.guideline.gov/help-and-about/summaries/determining-extent-adherence-to-the-iom-standards-in-ngc"><span class="screen-reader-text">More about NGC's appraisal</span></a></th>
<th id="standard">Standard of Trustworthiness</th>
</tr>
</thead>
<tbody>
<tr>
<td class="topborderme" headers="section">Yes</td>
<td class="greenboldme topborderme" headers="standard">Disclosure of Guideline Funding Source</td>
</tr>
<tr>
<td class="topborderme" headers="section"> <span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-3.png" alt="Good"/></span>
</td>
<td class="greenboldme topborderme" headers="standard">Disclosure and Management of Financial Conflict of Interests</td>
</tr>
<tr>
<td class="topborderme" id="blank"></td>
<th class="greenboldme topborderme" id="185" headers="standard">Guideline Development Group Composition</th>
</tr>
<tr>
<td headers="section">
Yes
</td>
<td class="leftpadme" headers="185">Multidisciplinary Group</td>
</tr>
<tr>
<td headers="section">
Yes
</td>
<td class="leftpadme" headers="186">Methodologist Involvement</td>
</tr>
<tr>
<td headers="section">
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-1.png" alt="Poor"/></span>
</td>
<td class="leftpadme" headers="187">Patient and Public Perspectives</td>
</tr>
<tr>
<td class="topborderme" id="blank"></td>
<th class="greenboldme topborderme" id="188" headers="standard">Use of a Systematic Review of Evidence</th>
</tr>
<tr>
<td headers="section">
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-5.png" alt="Excellent"/></span>
</td>
<td class="leftpadme" headers="188">Search Strategy</td>
</tr>
<tr>
<td headers="section">
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-3.png" alt="Good"/></span>
</td>
<td class="leftpadme" headers="189">Study Selection</td>
</tr>
<tr>
<td headers="section">
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-4.png" alt="Very Good"/></span>
</td>
<td class="leftpadme" headers="190">Synthesis of Evidence</td>
</tr>
<tr>
<td class="topborderme" id="blank"></td>
<th class="greenboldme topborderme" id="191" headers="standard">Evidence Foundations for and Rating Strength of Recommendations</th>
</tr>
<tr>
<td headers="section">
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-2.png" alt="Fair"/></span>
</td>
<td class="leftpadme" headers="191">Grading the Quality or Strength of Evidence</td>
</tr>
<tr>
<td headers="section">
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-5.png" alt="Excellent"/></span>
</td>
<td class="leftpadme" headers="192">Benefits and Harms of Recommendations</td>
</tr>
<tr>
<td headers="section">
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-5.png" alt="Excellent"/></span>
</td>
<td class="leftpadme" headers="193">Evidence Summary Supporting Recommendations</td>
</tr>
<tr>
<td headers="section">
<span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-4.png" alt="Very Good"/></span>
</td>
<td class="leftpadme" headers="194">Rating the Strength of Recommendations</td>
</tr>
<tr>
<td class="topborderme" headers="section"> <span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-5.png" alt="Excellent"/></span>
</td>
<td class="greenboldme topborderme" headers="standard">Specific and Unambiguous Articulation of Recommendations</td>
</tr>
<tr>
<td class="topborderme" headers="section"> <span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-1.png" alt="Poor"/></span>
</td>
<td class="greenboldme topborderme" headers="standard">External Review</td>
</tr>
<tr>
<td class="topborderme" headers="section"> <span class="rating"><img src="/web/20180712210119im_/https://www.guideline.gov/UI/images/rating-3.png" alt="Good"/></span>
</td>
<td class="greenboldme topborderme" headers="standard">Updating</td>
</tr>
</tbody>
</table>
</div>
<!-- /.content-tab-panel -->
<!-- /.content-tab-panel -->
<!-- TOOLBAR -->
<div class="content-toolbar">
<!-- Primary -->
<ul class="tools primary-tools">
<li class="dropdown tool sections">
<a href="#" class="tool-button">Sections</a>
<div class="dropdown-panel">
<ul class="section-links">
<li><a href="#420" class="section-mark">Recommendations</a></li>
<li><a href="#396" class="section-mark">Scope</a></li>
<li><a href="#405" class="section-mark">Methodology</a></li>
<li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
<li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
<li><a href="#430" class="section-mark">Contraindications</a></li>
<li><a href="#432" class="section-mark">Qualifying Statements</a></li>
<li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
<li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
<li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
<li><a href="#99999" class="section-mark">Disclaimer</a></li>
</ul>
</div>
<!-- /.dropdown-panel -->
</li>
</ul>
<!-- Other -->
<ul class="tools other-tools">
<li class="dropdown tool">
<a href="#" class="tool-button">Download</a>
<div class="dropdown-panel">
<ul>
<li><a href="/web/20180712210119/https://www.guideline.gov/summaries/downloadcontent/ngc-11330?contentType=pdf" class="pdf">.PDF 151.7 kb</a></li>
<li><a href="/web/20180712210119/https://www.guideline.gov/summaries/downloadcontent/ngc-11330?contentType=word" class="word">Word Document 360.3 kb</a></li>
<li><a href="/web/20180712210119/https://www.guideline.gov/summaries/downloadcontent/ngc-11330?contentType=xml" class="xml">.XML 95.7 kb</a></li>
</ul>
</div>
<!-- /.dropdown-panel -->
</li>
<li class="dropdown tool">
<a href="#" class="tool-button">Share</a>
<div class="dropdown-panel">
<ul class="toolbar-social">
<li><a target="_blank" href="https://web.archive.org/web/20180712210119/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/51252/acr-appropriateness-criteria--abdominal-aortic-aneurysm-interventional-planning-and-followup" class="facebook">Facebook</a></li>
<li><a target="_blank" href="https://web.archive.org/web/20180712210119/https://twitter.com/share?text=&url=https://www.guideline.gov/summaries/summary/51252/acr-appropriateness-criteria--abdominal-aortic-aneurysm-interventional-planning-and-followup" class="twitter">Twitter</a></li>
<li><a target="_blank" href="https://web.archive.org/web/20180712210119/https://www.linkedin.com/shareArticle?mini=true&url=https://www.guideline.gov/summaries/summary/51252/acr-appropriateness-criteria--abdominal-aortic-aneurysm-interventional-planning-and-followup&title=&summary=&source=" class="linkedin">Linkedin</a></li>
<li><a href="https://web.archive.org/web/20180712210119/mailto:/?Subject=AHRQ: ACR Appropriateness Criteria&amp;reg; abdominal aortic aneurysm: interventional planning and follow-up.&body=https://www.guideline.gov/summaries/summary/51252/acr-appropriateness-criteria--abdominal-aortic-aneurysm-interventional-planning-and-followup" class="email">Email</a></li>
</ul>
</div>
<!-- /.dropdown-panel -->
</li>
<li class="dropdown tool">
<a href="#" class="tool-button">Cite</a>
<div class="dropdown-panel citation">
<p class="text-label"><label for="citation">Citation: </label></p>
<textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: ACR Appropriateness Criteria® abdominal aortic aneurysm: interventional planning and follow-up. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2017 Jan 01. [cited 2018 Jul 12]. Available: https://www.guideline.gov</textarea>
<p class="text-label">Download citation file: </p>
<ul>
<li><a href="/web/20180712210119/https://www.guideline.gov/summaries/citedownload/51252?format=ris">RIS (Zotero)</a></li>
<li><a href="/web/20180712210119/https://www.guideline.gov/summaries/citedownload/51252?format=enw">EndNote</a></li>
<li><a href="/web/20180712210119/https://www.guideline.gov/summaries/citedownload/51252?format=bibtex">BibTex</a></li>
<li><a href="/web/20180712210119/https://www.guideline.gov/summaries/citedownload/51252?format=txt">Medlars</a></li>
<li><a href="/web/20180712210119/https://www.guideline.gov/summaries/citedownload/51252?format=ris">ProCite</a></li>
<li><a href="/web/20180712210119/https://www.guideline.gov/summaries/citedownload/51252">RefWorks</a></li>
<li><a href="/web/20180712210119/https://www.guideline.gov/summaries/citedownload/51252?format=ris">Reference Manager</a></li>
</ul>
</div>
<!-- /.dropdown-panel -->
</li>
<li class="tool">
<a href="#" id="51252" data-alert="SignInLanding" class="tool-button save-link">Save</a>
</li>
</ul>
<!-- Accordion -->
<ul class="tools accordion-controls">
<li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
<li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
</ul>
</div>
<!-- /.toolbar -->
<!-- ARTICLE -->
<div class="article" id="article">
<!-- ACCORDION -->
<div class="accordion-container" role="tablist" multiselectable="true">
<h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Major Recommendations</a></h3>
<p><div class="content_para"><p><strong><span style="text-decoration: underline;">ACR Appropriateness Criteria®</span></strong></p>
<p><strong>Abdominal Aortic Aneurysm (AAA): Interventional Planning and Follow-up</strong></p>
<p><strong><span style="text-decoration: underline;">Variant 1</span>: Planning for pre-endovascular repair (EVAR) or open repair of AAA</strong>.</p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Variant 1: Planning for pre-endovascular repair (EVAR) or open repair of AAA">
<thead>
<tr>
<th width="30%" class="Center" valign="top" scope="col">Procedure</th>
<th width="35%" class="Center" valign="top" scope="col">Appropriateness Category</th>
<th width="35%" class="Center" valign="top" scope="col">Relative Radiation Level</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top">CTA abdomen and pelvis with IV contrast</td>
<td class="Center" valign="top">Usually Appropriate</td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 5" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">MRA abdomen and pelvis without and with IV contrast</td>
<td class="Center" valign="top">Usually Appropriate</td>
<td class="Center" valign="top">O</td>
</tr>
<tr>
<td valign="top">MRA abdomen and pelvis without IV contrast</td>
<td class="Center" valign="top">May Be Appropriate </td>
<td class="Center" valign="top">O</td>
</tr>
<tr>
<td valign="top">CT abdomen and pelvis with IV contrast</td>
<td class="Center" valign="top">May Be Appropriate </td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">CT abdomen and pelvis without IV contrast</td>
<td class="Center" valign="top">May Be Appropriate</td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">Aortography abdomen</td>
<td class="Center" valign="top">May Be Appropriate </td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">CT abdomen and pelvis without and with IV contrast</td>
<td class="Center" valign="top">May Be Appropriate </td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">US aorta abdomen with duplex Doppler</td>
<td class="Center" valign="top">Usually Not Appropriate</td>
<td class="Center" valign="top">O</td>
</tr>
<tr>
<td valign="top">X-ray abdomen and pelvis</td>
<td class="Center" valign="top">Usually Not Appropriate</td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">CT abdomen and pelvis without IV contrast and US aorta abdomen with duplex Doppler</td>
<td class="Center" valign="top">Usually Not Appropriate </td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
</tbody>
</table>
<p>Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.</p>
<p><strong><span style="text-decoration: underline;">Variant 2</span>: Follow-up for post-endovascular repair (EVAR) or open repair of AAA</strong>.</p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Variant 2: Follow-up for post-endovascular repair (EVAR) or open repair of AAA">
<thead>
<tr>
<th width="30%" class="Center" valign="top" scope="col">Procedure</th>
<th width="35%" class="Center" valign="top" scope="col">Appropriateness Category</th>
<th width="35%" class="Center" valign="top" scope="col">Relative Radiation Level</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top">CTA abdomen and pelvis with IV contrast</td>
<td class="Center" valign="top">Usually Appropriate</td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 5" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">MRA abdomen and pelvis without and with IV contrast</td>
<td class="Center" valign="top">Usually Appropriate</td>
<td class="Center" valign="top">O</td>
</tr>
<tr>
<td valign="top">Aortography abdomen</td>
<td class="Center" valign="top">May Be Appropriate</td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">CT abdomen and pelvis without and with IV contrast</td>
<td class="Center" valign="top">May Be Appropriate</td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">CT abdomen and pelvis without IV contrast and US aorta abdomen with duplex Doppler</td>
<td class="Center" valign="top">May Be Appropriate</td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">MRA abdomen and pelvis without IV contrast</td>
<td class="Center" valign="top">May Be Appropriate</td>
<td class="Center" valign="top">O</td>
</tr>
<tr>
<td valign="top">US aorta abdomen with duplex Doppler</td>
<td class="Center" valign="top">May Be Appropriate</td>
<td class="Center" valign="top">O</td>
</tr>
<tr>
<td valign="top">CT abdomen and pelvis without IV contrast</td>
<td class="Center" valign="top">May Be Appropriate</td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">CT abdomen and pelvis with IV contrast</td>
<td class="Center" valign="top">May Be Appropriate (Disagreement)</td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
<tr>
<td valign="top">X-ray abdomen and pelvis</td>
<td class="Center" valign="top">May Be Appropriate</td>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif"/></td>
</tr>
</tbody>
</table>
<p>Note: Abbreviations used in the tables are listed at the end of the "Major Recommendations" field.</p>
<p><span style="text-decoration: underline;"><strong>Summary of Literature Review</strong></span></p>
<p><strong>Introduction/Background</strong></p>
<p>In 1991, a group of investigators reported successful deployment of an endoluminal stent graft within the aorta via a transfemoral approach. It permanently transformed the landscape of AAA management and therapy. Previous treatment options were limited to expectant management combining medical blood pressure control with close imaging surveillance versus traditional open surgical repair. Given the significant perioperative morbidity of open repair, the point of transition to surgical intervention varied on a case-by-case basis. Guidelines for AAA screening were subsequently established to assist medical decision making. These guidelines were developed based on a patient's health status, comorbidities, the aneurysm's maximum diameter (>5.5 cm) and rate of change (>1 cm/year) and other signs that indicated impending rupture. The arrival of the endovascular aneurysm repair (EVAR) technique introduced new variables to managing AAAs. Relatively recent development of the fenestrated endovascular aneurysm repair (FEVAR) and percutaneous endovascular aneurysm repair (PEVAR) has advanced therapeutic potential while maintaining low morbidity.</p>
<p>Multiple studies have shown significantly decreased length of hospital stay and decreased perioperative morbidity with EVAR compared to open repair. Despite this, open repair is still performed in patients with unsuitable aneurysm morphology for EVAR and in those with failed EVAR. For patients who present de novo for treatment of AAA without any prior imaging available, the entire aorta (including the thoracic portion) should be assessed to fully characterize the aneurysm and to exclude a concomitant thoracic aortic aneurysm. Preoperative imaging for open repair of AAA has one primary focus: to determine the need for surgery based on aneurysm size, extent, and rate of growth. Additional information regarding potential variant anatomy can also be helpful in guiding appropriate treatment and preventing unexpected complications at the time of repair.</p>
<p>EVAR requires accurate preoperative imaging evaluation for appropriate patient selection based on aneurysm morphology, access vessel size, and patency. Paramount considerations in evaluating an AAA for EVAR lie in the morphology of the proximal neck, which for an infrarenal AAA is defined as the segment of aorta between the most caudal renal artery and the proximal boundary of the aneurysm. Unfavorable neck anatomy, based on its diameter, length, angulation, morphology, and presence of calcification, is the most frequent cause of exclusion from EVAR. Over 50% of patients have aneurysm morphology unsuitable for conventional EVAR. In conventional EVAR, a neck size of >10 to 15 mm in length and <30 mm in diameter is required to provide an adequate proximal graft seal. Although not an absolute contraindication to EVAR, mural thrombus and atherosclerotic calcification covering more than 90º of the circumference of the aortic diameter in the proximal neck is associated with a higher risk for type I endoleak and stent-graft migration. The distal landing zone is usually located within one or both of the common iliac arteries. With newer-generation devices, common iliac artery diameters of ≤20 mm can be considered for EVAR. The minimal external iliac artery intraluminal diameter should be ≥7 mm to safely accept delivery sheaths.</p>
<p>In recent years, new devices have become available to mitigate unfavorable aortic neck anatomy. Several designs feature an uncovered proximal portion that allows for placement of the stent directly at the origin of aortic branches, whereas others possess ready-made vessel origins for placement within the renal and mesenteric arteries. FEVAR is an alternative approach for those with aortic necks of inadequate length. In FEVAR, fenestrations within the graft material allow for perfusion of major visceral arteries while securing an adequate proximal seal. A variant of the FEVAR technique describes the placement of bridging stents through these fenestrations. Such devices may be especially favorable in women, as these patients are less likely to have aneurysm neck and iliac diameters sufficient for traditional EVAR. FEVAR obviates the need for open femoral exposure and offers the benefit of shorter procedure times, lower complication rates, and shorter hospital stays. FEVAR requires common femoral artery anatomy that is suitable for percutaneous access and free of significant calcification. Candidates for FEVAR should be carefully selected, as the presence and degree of vessel calcification is a major determinant of technical failure.</p>
<p>The advantages of EVAR come at a cost of lifelong imaging surveillance. This is due to higher rate of complications that require reintervention compared to open repair. Complications of EVAR include stent graft migration, kinking, infection, thrombosis, and renal dysfunction. The most important complication to detect is continued aneurysm expansion leading to eventual rupture, which can occur even after successful EVAR. The most common complication of EVAR is endoleak formation, which may contribute to aneurysm sac enlargement and rupture. Endoleaks are classified by their etiology, with types I and III most commonly leading to rupture. Appropriate classification is therefore crucial for subsequent management and should be clarified whenever possible. Although EVAR is safe and has a low mortality rate, the possibility of complications and need for reintervention remains high, thereby requiring life-long monitoring.</p>
<p>The ultimate goal of endovascular therapy is to prevent aneurysm rupture. Follow-up imaging is the most useful tool for evaluating post-therapeutic outcomes and monitoring potential complications. Successful therapy results in an aneurysm that remains stable or decreases in size over serial follow-up imaging examinations, with decreasing size of the aneurysm sac believed to indicate a low risk of future rupture All available imaging modalities have been investigated over time for their efficacy in post-EVAR follow-up. According to Society of Interventional Radiology guidelines, the imaging modality of choice should allow at least (1) measurement of aortic aneurysm diameter, (2) detection and classification of endoleaks, and (3) detection of morphologic details of the stent grafts. Imaging modalities should be assessed by their effectiveness in satisfying these three parameters, as well as their respective safety profiles, including use of ionizing radiation and potentially nephrotoxic contrast material.</p>
<p><strong>Overview of Imaging Modalities</strong></p>
<p><em>CT and CTA</em></p>
<p>Computed tomography (CT) is a cross-sectional imaging modality that offers excellent spatial resolution, fast image acquisition times, and widespread availability. However, without contrast material administration, its ability to assess vascular structures is limited. Evaluation of the vessel lumen is accomplished through CT angiography (CTA), a technique that utilizes the administration of iodinated contrast material. The addition of 3-D volumetric postprocessing techniques allow the abdominal aorta and associated vasculature to be viewed in any obliquity and affords quantification of luminal diameter, cross-sectional area, and sac volume. A disadvantage of CTA includes potential nephrotoxicity from administered contrast material. </p>
<p>For the purposes of distinguishing between CT and CTA, the ACR Appropriateness Criteria topics use the definition in the <a href="/web/20180712210119/https://www.guideline.gov/Home/Disclaimer?id=51252&contentType=summary&redirect=https%3a%2f%2fwww.acr.org%2f-%2fmedia%2fACR%2fFiles%2fPractice-Parameters%2fbody-cta.pdf%3fla%3den" title="ACR Web site">Practice Parameter for the Performance and Interpretation of Body Computed Tomography Angiography (CTA)</a> <img alt="External Web Site Policy" src="/web/20180712210119im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>: "<em>CTA uses a thin-section CT acquisition that is timed to coincide with peak arterial or venous enhancement. The resultant volumetric dataset is interpreted using primary transverse reconstructions as well as multiplanar reformations and 3D renderings</em>." </p>
<p>All procedure elements are essential: (1) timing, (2) recons/reformats, and (3) 3-D renderings. Standard CTs with contrast also include timing issues and recons/reformats. Only in CTA, however, is 3-D rendering a required element. This corresponds to the definitions that the Centers for Medicare & Medicaid Services (CMS) has applied to the Current Procedural Terminology (CPT) codes. </p>
<p>CTA imaging may be performed as a single arterial phase, biphasic study (noncontrast and arterial or arterial and delayed phases), or as a triphasic study (noncontrast, arterial, and delayed phases). To reduce the cumulative lifetime radiation dose of patients undergoing CTA surveillance, several authors have proposed eliminating either the arterial phase or delayed phase, although one author has suggested eliminating noncontrast scans from all surveillance examinations with the exception of an initial 1-month follow-up. </p>
<p>Several studies have reported significant dose reduction using dual-energy CT with acquisition of delayed-phase images only. Accompanying software allows for the isolation of iodine from a selected region and enables reconstruction of virtual noncontrast images. A colored overlay can be applied to voxels containing iodine, rendering detection of contrast material within the aneurysm sac external to the stent-graft more visible. Dual-phase dual-energy CT can potentially reduce the radiation dose by 19.5% when compared to a standard triphasic CT examination. Additional dose reduction techniques include the use of automatic exposure control and iterative reconstruction algorithms.</p>
<p>Determining the optimal dose-efficient CT technique is a work in progress that will continue to evolve with increased experience and technological advancement. </p>
<p><em>Aortography</em></p>
<p>Aortography is an invasive imaging modality that can accurately assess aortic side branch patency, knowledge of which is crucial for deployment of conventional and fenestrated endografts with or without bridging stents. However, it fails to demonstrate mural thrombus, thereby limiting diameter measurements and landing zone assessment. Though less sensitive than CTA in detecting endoleaks, aortography is able to demonstrate the direction of blood flow in or out of the aneurysm sac, rendering it more accurate than CTA in classifying endoleaks. Although traditional aortography relies on iodinated contrast material, recent studies suggest that carbon dioxide may be an acceptable alternative for evaluating endoleaks in patients at risk for contrast-related nephropathy. </p>
<p><em>MRA</em></p>
<p>The major advantage of magnetic resonance angiography (MRA) relative to CTA is improved soft tissue characterization. Despite relatively low nephrotoxicity, gadolinium-based contrast media (GBCM) have been linked to nephrogenic systemic fibrosis (NSF). As such, evaluation of renal function in high-risk patients before administering a GBCM is recommended. Disadvantages of MRA include relatively long scanning duration, patient claustrophobia, decreased spatial resolution, and contraindication in patients with certain implantable devices. MRA is also limited in its ability to detect intimal calcification. Additionally, susceptibility artifact from the metal interstices of the stent graft presents a diagnostic challenge for assessing device integrity and may mimic graft stenosis. Although the presence of an implanted cardiac pacemaker was previously an absolute contraindication to magnetic resonance imaging (MRI), several new models are FDA-approved for conditional use. </p>
<p>Superior soft-tissue characterization inherent to MRA may assist clinicians in differentiating slow-growing aneurysms from fast-growing aneurysms. A recent study demonstrated that AAAs containing intraluminal thrombus that have high T1-weighted signal intensity are associated with higher growth rates.</p>
<p><em>US</em></p>
<p>Color duplex ultrasound (CDUS) is a noninvasive imaging modality that is portable and safe, sparing patients from nephrotoxic contrast material administration. CDUS is able to assess blood flow dynamics in real-time and allows for quantification of luminal diameter and cross-sectional area. Image quality in CDUS is highly dependent on operator experience, patient cooperation, and patient body habitus. Although excellent correlation between AAA diameter measurements made by CT and CDUS is well documented, there is general agreement that conventional ultrasound (US) techniques systematically underestimate aneurysm diameter by ~2 mm. </p>
<p>Contrast-enhanced ultrasound (CEUS) utilizes the infusion of stabilized sodium hexafluoride gas to visualize the vessel lumen. Unlike iodinated contrast materials used in CTA, this gas is not nephrotoxic and is safely eliminated via the respiratory system. The advent of 3-D CEUS utilizes positional information for magnetic field emitters to assemble collected US reflections into a high-resolution 3-D image, which results in improved image quality relative to CDUS. 3-D CEUS is reported to be more accurate than 2-D methods in quantifying maximum vessel diameter, as the former allows measurements to be made orthogonal to vessel centerline. </p>
<p>For patients with absolute contraindications to iodinated contrast material, whether due to severe renal impairment or life-threatening contrast allergy, US is an important adjunct to nonenhanced CT.</p>
<p><strong>Discussion of Procedures by Variant</strong></p>
<p><em>Variant 1: Planning for Pre-endovascular Repair (EVAR) or Open Repair of AAA</em></p>
<p><span style="text-decoration: underline;">Radiography</span></p>
<p>Radiographs are unable to adequately visualize the abdominal aorta, thereby prohibiting proximal landing zone assessment and luminal diameter quantification. As such, there is no role for radiography in the preoperative evaluation of AAA. However, given the high spatial resolution of radiography, this modality affords optimal visualization of stent graft geometry. When utilizing consistent centering protocols, this allows for reliable detection of kinks and stent graft migration to within 2 mm. </p>
<p><span style="text-decoration: underline;">CT and CTA</span></p>
<p>Due to its superior spatial resolution and rapid image acquisition, CTA with 3-D volumetric reconstruction and vessel analysis has gained wide acceptance as the gold standard for pre-EVAR evaluation. The utilization of 3-D reconstruction software has become paramount in EVAR planning, as it diminishes the impact of vessel tortuosity on diameter and length measurements, in addition to reducing intraobserver variability. One author found that routine 3-D analysis of pre-EVAR images led to a significant reduction in type I endoleaks. Reformatted CTA images in the coronal and sagittal planes should be utilized for increased diagnostic accuracy. In most cases, a CTA of the abdomen and pelvis is appropriate to ensure coverage of the entire aneurysm and vascular access. The CTA should include the chest in patients with thoracoabdominal aortic aneurysms (TAAA). </p>
<p><span style="text-decoration: underline;">Aortography</span></p>
<p>As aortography and radiography are unable to accurately provide aneurysm sac diameter measurements and landing zone assessment, these modalities are inadequate for pre-EVAR or open repair evaluation. However, aortography may be of value in assessing branch vessel patency and is usually part of branch vessel occlusion procedures before aneurysm repair. </p>
<p><span style="text-decoration: underline;">MRA</span></p>
<p>For the purpose of pre-EVAR planning, T1-weighted spin-echo images and flow-based methods such as time of flight or phase contrast provide adequate details regarding aneurysm morphology and relevant vascular anatomy. However, these techniques are limited by low spatial resolution and signal-to-noise ratio and are therefore suboptimal for evaluating small-vessel lesions or diminutive side branches. Furthermore, flow-based sequences are susceptible to flow artifacts that may overestimate the degree of stenosis or falsely demonstrate an occlusion. To overcome these limitations, contrast-enhanced MRA (CE-MRA) should be added to conventional T1- and T2-weighted spin-echo sequences. CE-MRA is much less susceptible to flow and susceptibility artifacts and has a high signal-to-noise ratio for evaluating small vessels and fine structural details. The effectiveness of CE-MRA has been found to be comparable to that of CTA in assessing the suitability of aneurysms for EVAR. In most cases, an MRA of the abdomen and pelvis is appropriate to ensure coverage of the entire aneurysm and vascular access. The MRA should include the chest in patients with TAAA. </p>
<p>Acquisition of noncontrast balanced steady state free precession (bSSFP) images may be useful in the preoperative evaluation of patients who poorly tolerate GBCM or are at risk for NSF. One study found that AAA measurements obtained by noncontrast MRA were not significantly different from those measured by CTA. </p>
<p><span style="text-decoration: underline;">US</span></p>
<p>Although the United States Preventative Services Task Force currently recommends one-time US screening for AAA in men ages 65 to 75 years who have ever smoked, no evidence is present within the medical literature to support the use of either CDUS or CEUS in the formal preoperative evaluation of AAA.</p>
<p><em>Variant 2: Follow-up for Post-endovascular Repair (EVAR) or Open Repair of AAA</em></p>
<p><span style="text-decoration: underline;">CT and CTA</span></p>
<p>The exceptional spatial resolution and fast imaging speeds of CTA has made it the de facto gold standard for post-EVAR and post-open repair imaging surveillance. After EVAR, the most widely used surveillance regimen utilizes multiphasic contrast-enhanced CT at 1 month, 12 months, and yearly thereafter. If an abnormality is detected 1 month post-EVAR, a follow-up scan at 6 months is performed. In the absence of adverse outcomes at the 1-month follow-up imaging, the intensity and frequency of the surveillance program may be modulated accordingly. Compared to aortography, CTA has higher sensitivity in detecting endoleaks after EVAR. Compared to US, CTA is better able to visualize kinking and migration of the stent-graft and is equivalent in quantifying aneurysm sac size.</p>
<p>Initial post-EVAR surveillance studies monitored the maximum diameter of the aneurysm sac as a marker for response to therapy. This method has been shown to be unreliable due to substantial interobserver variability. Volume analysis of the aneurysm sac has since proven to be the most reliable indicator for aneurysm rupture and/or need for reintervention. In an effort to reduce radiation dose and contrast material exposure, several authors have proposed using serial volumetric analysis of AAAs with noncontrast CT as the sole screening test for post-EVAR follow-up. Volume discrepancy due to interoperator variability has been demonstrated to be less than 2% when the procedure is performed by experienced personnel. In patients in whom contrast materials are contraindicated, serial volume measurements of the nonenhanced aneurysm sac provides valuable information in guiding management. </p>
<p>In most cases, a CTA of the abdomen and pelvis is appropriate to ensure coverage of the treated aneurysm and stent graft. The CTA should include the chest in patients with TAAA.</p>
<p><span style="text-decoration: underline;">Aortography</span></p>
<p>Due to the relatively invasive nature of aortography, it is not practical for routine post-EVAR surveillance. However, in the setting of a known endoleak, aortography may be more accurate than CTA in classifying endoleaks. One study revealed only 86% agreement in endoleak classification between aortography and CTA, in which subsequent correct classification by aortography significantly improved patient management. It therefore stands to reason that aortography may be best utilized as a second-line imaging modality in post-EVAR patients, playing a vital role in endoleak classification and reintervention.</p>
<p><span style="text-decoration: underline;">MRA</span></p>
<p>When considering using MRA for post-EVAR surveillance, stent material and orientation are important considerations. Typical stent construction employs nitinol, elgiloy, or stainless steel. Nitinol is a nickel-titanium alloy that causes relatively few artifacts on MRA, while allowing adequate visualization of the stent lumen and adjacent structures. Elgiloy is an alloy of cobalt, chromium, and nickel that may obscure the stent lumen but still allows for visualization of adjacent structures. Patients with nitinol stents are the optimal candidates for MRA, while those with elgiloy or stainless steel stents may experience significant artifacts that compromise visualization of the stent lumen and limit morphological resolution of the stent wall. However, artifacts may arise even with nitinol stents secondary to stent geometry. Due to severe susceptibility artifact associated with stainless steel embolization coils, MRA is poor in the follow-up of patients who have undergone coil embolization of the internal iliac artery before EVAR.</p>
<p>MRA of the post-EVAR aorta shares multiple features with CTA. Like CTA, isotropic 3-D MRA images may be reformatted in any plane for volume analysis or orthogonal diameter measurements. In patients with nitinol stents, aortic diameter measurements for MRA have been shown to be as reliable as those obtained with CTA. MRA has been shown to be more sensitive than CTA for the detection of endoleaks. Consequently, the higher rate of endoleak detection seen by MRA in cases with a negative CTA may shed light on the phenomenon of endotension. More recently, time-resolved MRA has been used in the characterization of endoleaks and may provide relevant information regarding contrast and flow dynamics within endoleaks. As such, replacing aortography as an effective and noninvasive method for endoleak characterization shows promise.</p>
<p>In most cases, MRA of the abdomen and pelvis is appropriate to ensure coverage of the treated aneurysm and stent graft. The MRA should include the chest in patients with TAAA.</p>
<p>Blood pool contrast materials such as ferumoxytol remain intravascular for a prolonged duration, thereby allowing for generation of high-resolution 3-D multiplanar images. Use of these contrast materials may improve detection of slow-flow endoleaks. </p>
<p>Patients intolerant of GBCM or those at risk for NSF may benefit from the acquisition of noncontrast bSSFP images in post-EVAR surveillance. One small retrospective study found that noncontrast bSSFP images can be used to exclude endoleak after EVAR, with postcontrast imaging reserved for verification and further characterization of a suspected endoleak.</p>
<p><span style="text-decoration: underline;">US</span></p>
<p>CDUS and CEUS are being increasingly recommended for post-EVAR follow-up. These are convenient, noninvasive, and have a favorable safety profile. In the evaluation of endoleak, CDUS has high specificity but limited sensitivity, reported in two large meta-analyses to be 91% to 93% and 66% to 69%, respectively. The major limitations of US are the inability to detect stent-graft kinking, fracture, migration, or component separation. For this reason, adjunct four-view radiographs are recommended to be obtained with all post-EVAR US examinations. For FEVARs that involve the celiac trunk, US is unable to adequately visualize the proximal sealing zone. </p>
<p>Not unexpectedly, published results regarding the accuracy of CDUS in post-EVAR follow-up are varied. Nevertheless, US offers the ability to determine endoleak flow direction and therefore assist in guiding management. Spectral waveform analysis of reperfusion to the aneurysm sac has been shown to have prognostic value, in which type II endoleaks with bidirectional flow and low flow velocities have been associated with spontaneous closure.</p>
<p>Several studies have compared 2-D CEUS to CDUS in the setting of post-EVAR follow-up, with a recent meta-analysis finding no clinically significant differences between the two. In the setting of post-FEVAR follow-up, 2-D CEUS was found to be equivalent to CTA in aneurysm sac measurement and in assessing patency of visceral vessels. Additional studies have demonstrated the superiority of 3-D CEUS over standard 2-D methods in both endoleak detection and sac measurement. Three-dimensional CEUS has been found to be equivalent or superior to CTA in endoleak detection and sac measurement, in addition to being highly reproducible. </p>
<p>Many have advocated replacing CTA with US for post-EVAR surveillance due to its lack of exposure to nephrotoxic contrast. Specifically, it has been suggested that CDUS be used in conjunction with noncontrast CT to follow patient's post-EVAR who have renal insufficiency. US surveillance protocols currently being developed seek to drastically reduce the cost of follow-up without compromising accuracy, with CTA reserved for further evaluation of suspicious findings.</p>
<p><span style="text-decoration: underline;">Radiography</span></p>
<p>Radiographs were previously considered a useful adjunct to CT for detecting stent graft migration and underlying structural change. This modality cannot be used as a stand-alone study, as it is unable to assess aneurysm sac size or detect endoleak. Radiography alone therefore does not meet guideline criteria outlined by the Society of Interventional Radiology in AAA postoperative surveillance. Despite its limitations, anterior and lateral radiographs have been shown to be useful for detecting stent migration, kinking, or modular separation of the stent graft components, whereas oblique projections may detect wire fractures. Three-dimensional–reconstructed CTA images also provide this information, in addition to detecting endoleaks and changes in aneurysm size. As such, advances in 3-D visualization tools will likely render radiographs redundant and unnecessary when used in conjunction with CT. However, if US is used as the primary imaging modality in post-EVAR surveillance, radiographs become a vital adjunct examination.</p>
<p><strong>Summary of Recommendations</strong></p>
<ul style="list-style-type: disc;">
<li>For preoperative AAA repair planning, CTA abdomen and pelvis and MRA abdomen and pelvis are appropriate procedures. </li>
<li>After repair of AAA, CTA abdomen and pelvis and MRA abdomen and pelvis are appropriate procedures. </li>
</ul>
<p><strong>Abbreviations</strong></p>
<ul style="list-style-type: disc;">
<li>AAA, abdominal aortic aneurysm </li>
<li>CT, computed tomography </li>
<li>CTA, computed tomography angiography </li>
<li>EVAR, endovascular aneurysm repair </li>
<li>IV, intravenous </li>
<li>MRA, magnetic resonance angiography </li>
<li>US, ultrasound </li>
</ul>
<p><strong>Relative Radiation Level Designations</strong></p>
<table border="1" cellspacing="3" cellpadding="5" summary="Table: Relative Radiation Level Definitions">
<thead>
<tr>
<th class="Center" valign="top" scope="col">Relative Radiation Level*</th>
<th class="Center" valign="top" scope="col">Adult Effective Dose Estimate Range</th>
<th class="Center" valign="top" scope="col">Pediatric Effective Dose Estimate Range</th>
</tr>
</thead>
<tbody>
<tr>
<td class="Center" valign="top">O</td>
<td class="Center" valign="top">0 mSv</td>
<td class="Center" valign="top">0 mSv</td>
</tr>
<tr>
<td class="Center" valign="top"><img alt="radioactive symbol" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/></td>
<td class="Center" valign="top"><0.1 mSv</td>
<td class="Center" valign="top"><0.03 mSv</td>
</tr>
<tr>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/></td>
<td class="Center" valign="top">0.1-1 mSv</td>
<td class="Center" valign="top">0.03-0.3 mSv</td>
</tr>
<tr>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/></td>
<td class="Center" valign="top">1-10 mSv</td>
<td class="Center" valign="top">0.3-3 mSv</td>
</tr>
<tr>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/></td>
<td class="Center" valign="top">10-30 mSv</td>
<td class="Center" valign="top">3-10 mSv</td>
</tr>
<tr>
<td class="Center" valign="top"><img alt="radioactive symbol 1" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive symbol 2" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive symbol 3" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive symbol 4" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/> <img alt="radioactive symbol 5" src="https://web.archive.org/web/20180712210119im_/http://guideline.gov/images/image_radioactive.gif "/></td>
<td class="Center" valign="top">30-100 mSv</td>
<td class="Center" valign="top">10-30 mSv</td>
</tr>
<tr>
<td valign="top" colspan="3">*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (e.g., region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as "Varies."</td>
</tr>
</tbody>
</table></div></p>
<h3><a href="#">Clinical Algorithm(s)</a></h3>
<p><div class="content_para"><p>Algorithms were not developed from criteria guidelines.</p></div></p>
</div>
<h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Disease/Condition(s)</a></h3>
<p><div class="content_para"><p>Abdominal aortic aneurysm (AAA)</p></div></p>
<h3><a href="#">Guideline Category</a></h3>
<p>Evaluation</p>
<p>Management</p>
<p>Screening</p>
<p>Treatment</p>
<h3><a href="#">Clinical Specialty</a></h3>
<p>Cardiology</p>
<p>Family Practice</p>
<p>Internal Medicine</p>
<p>Radiology</p>
<p>Thoracic Surgery</p>
<h3><a href="#">Intended Users</a></h3>
<p>Advanced Practice Nurses</p>
<p>Health Care Providers</p>
<p>Hospitals</p>
<p>Managed Care Organizations</p>
<p>Physician Assistants</p>
<p>Physicians</p>
<p>Students</p>
<p>Utilization Management</p>
<h3><a href="#">Guideline Objective(s)</a></h3>
<p><div class="content_para"><p>To evaluate the appropriateness of imaging procedures for interventional planning and follow-up of abdominal aortic aneurysm (AAA)</p></div></p>
<h3><a href="#">Target Population</a></h3>
<p><div class="content_para"><p>Patients with an abdominal aortic aneurysm</p></div></p>
<h3><a href="#">Interventions and Practices Considered</a></h3>
<p><ol style="list-style-type: decimal;">
<li>Computed tomography angiography (CTA), abdomen and pelvis with intravenous (IV) contrast </li>
<li>Computed tomography (CT)
<ul style="list-style-type: disc;">
<li>Abdomen and pelvis without IV contrast </li>
<li>Abdomen and pelvis with IV contrast </li>
<li>Abdomen and pelvis without and with IV contrast </li>
</ul>
</li>
<li>Magnetic resonance angiography (MRA)
<ul style="list-style-type: disc;">
<li>Abdomen and pelvis without and with IV contrast </li>
<li>Abdomen and pelvis without IV contrast </li>
</ul>
</li>
<li>Aortography, abdomen </li>
<li>Ultrasound (US) aorta abdomen with duplex Doppler </li>
<li>X-ray, abdomen and pelvis </li>
<li>CT abdomen and pelvis without IV contrast and US aorta abdomen with duplex Doppler </li>
</ol></p>
<h3><a href="#">Major Outcomes Considered</a></h3>
<p><ul style="list-style-type: disc;">
<li>Utility of imaging procedures in interventional planning and follow-up of abdominal aortic aneurysm </li>
<li>Sensitivity, specificity, and accuracy of imaging procedures in interventional planning and follow-up of abdominal aortic aneurysm </li>
</ul></p>
</div>
<h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
<p>Hand-searches of Published Literature (Primary Sources)</p>
<p>Hand-searches of Published Literature (Secondary Sources)</p>
<p>Searches of Electronic Databases</p>
<h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
<p><div class="content_para"><p><strong><span style="text-decoration: underline;">Literature Search Summary</span></strong></p>
<p>Of the 70 citations in the original bibliography, 60 were retained in the final document. </p>
<p>A literature search was conducted in April 2015 and updated on August 2017 to identify additional evidence published since the <em>ACR Appropriateness Criteria® Abdominal Aortic Aneurysm: Interventional Planning and Follow-up</em> topic was finalized. Using the search strategy described in the literature search companion (see the "Availability of Companion Documents" field), 889 articles were found. 34 articles were added to the bibliography. One hundred and thirty-three articles were not used as they were duplicates already cited in the original bibliography or captured in more than one literature search. The remaining articles were not used due to either poor study design, the articles were not relevant or generalizable to the topic, or the results were unclear or biased. </p>
<p>The author added 3 citations from bibliographies, Web sites, or books that were not found in the literature searches. </p>
<p>Three citations are supporting documents that were added by staff.</p>
<p>See also the American College of Radiology (ACR) Appropriateness Criteria® literature search process document (see the "Availability of Companion Documents" field) for further information.</p></div></p>
<h3><a href="#">Number of Source Documents</a></h3>
<p><div class="content_para"><p>Of the 70 citations in the original bibliography, 60 were retained in the final document. The literature search conducted in April 2015 and updated in August 2017 found 34 articles that were added to the bibliography. The author added 3 citations from bibliographies, Web sites, or books that were not found in the literature searches. Three citations are supporting documents that were added by staff.</p></div></p>
<h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
<p>Weighting According to a Rating Scheme (Scheme Given)</p>
<h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
<p><div class="content_para"><p><span style="text-decoration: underline;"><strong>Definitions of Study Quality Categories</strong></span></p>
<p>Category 1 - The study is well-designed and accounts for common biases.</p>
<p>Category 2 - The study is moderately well-designed and accounts for most common biases.</p>
<p>Category 3 - The study has important study design limitations.</p>
<p>Category 4 - The study or source is not useful as primary evidence. The article may not be a clinical study, the study design is invalid, or conclusions are based on expert consensus.</p>
<p class="Indent">The study does not meet the criteria for or is not a hypothesis-based clinical study (e.g., a book chapter or case report or case series description);</p>
<p class="Indent"><em>Or</em></p>
<p class="Indent">The study may synthesize and draw conclusions about several studies such as a literature review article or book chapter but is not primary evidence;</p>
<p class="Indent"><em>Or</em></p>
<p class="Indent">The study is an expert opinion or consensus document.</p>
<p>Category M - Meta-analysis studies are not rated for study quality using the study element method because the method is designed to evaluate individual studies only. An "M" for the study quality will indicate that the study quality has not been evaluated for the meta-analysis study.</p></div></p>
<h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
<p>Review of Published Meta-Analyses</p>
<p>Systematic Review with Evidence Tables</p>
<h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
<p><div class="content_para"><p>The topic author assesses the literature then drafts or revises the narrative summarizing the evidence found in the literature. American College of Radiology (ACR) staff drafts an evidence table based on the analysis of the selected literature. These tables rate the study quality for each article included in the narrative.</p>
<p>The expert panel reviews the narrative, evidence table and the supporting literature for each of the topic-variant combinations and assigns an appropriateness rating for each procedure listed in the variant table(s). Each individual panel member assigns a rating based on his/her interpretation of the available evidence.</p>
<p>More information about the evidence table development process can be found in the ACR Appropriateness Criteria® Evidence Table Development document (see the "Availability of Companion Documents" field).</p></div></p>
<h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
<p>Expert Consensus (Delphi)</p>
<h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
<p><div class="content_para"><p><strong><span style="text-decoration: underline;">Overview</span></strong></p>
<p>The purpose of the rating rounds is to systematically and transparently determine the panels' recommendations while mitigating any undue influence of one or more panel members on another individual panel members' interpretation of the evidence. The panel member's rating is determined by reviewing the evidence presented in the Summary of Literature Review and assessing the risks or harms of performing the procedure or treatment balanced with the benefits of performing the procedure or treatment. The individual panel member ratings are used to calculate the median rating, which determines the panel's rating. The assessment of the amount of deviation of individual ratings from the panel rating determines whether there is disagreement among the panel about the rating. </p>
<p>The process used in the rating rounds is a modified Delphi method based on the methodology described in the RAND/UCLA Appropriateness Method User Manual. </p>
<p>The appropriateness is rated on an ordinal scale that uses integers from 1 to 9 grouped into three categories (see the "Rating Scheme for the Strength of the Recommendations" field).</p>
<p><strong><span style="text-decoration: underline;">Determining the Panel's Recommendation</span></strong> </p>
<ul style="list-style-type: disc;">
<li>Ratings represent an individual's assessment of the risks and benefits of performing a specific procedure for a specific clinical scenario on an ordinal scale. The recommendation is the appropriateness category (i.e., "Usually appropriate," "May be appropriate," or "Usually not appropriate"). </li>
<li>The appropriateness category for a procedure and clinical scenario is determined by the panel's median rating without disagreement (see below for definition of disagreement). The panel's median rating is calculated after each rating round. If there is disagreement after the second rating round, the rating category is "May be appropriate (Disagreement)" with a rating of "5" so users understand the group disagreed on the final recommendation. The actual panel median rating is documented to provide additional context. </li>
<li>Disagreement is defined as excessive dispersion of the individual ratings from the group (in this case, an Appropriateness Criteria [AC] panel) median as determined by comparison of the interpercentile range (IPR) and the interpercentile range adjusted for symmetry (IPRAS). In those instances when the IPR is greater than the IPRAS, there is disagreement. For a complete discussion, please refer to chapter 8 of the RAND/UCLA Appropriateness Method User Manual. </li>
<li>Once the final recommendations have been determined, the panel reviews the document. If two thirds of the panel feel a final recommendation is wrong (e.g., does not accurately reflect the evidence, may negatively impact patient health, has unintended consequences that may harm health care, etc.) and the process must be started again from the beginning. </li>
</ul>
<p>For additional information on the ratings process see the Rating Round Information document (see the "Availability of Companion Documents" field).</p>
<p>Additional methodology documents, including a more detailed explanation of the complete topic development process and all ACR AC topics can be found on the <a href="/web/20180712210119/https://www.guideline.gov/Home/Disclaimer?id=51252&contentType=summary&redirect=https%3a%2f%2fwww.acr.org%2fClinical-Resources%2fACR-Appropriateness-Criteria" title="ACR Web site">ACR Web site</a> <img alt="External Web Site Policy" src="/web/20180712210119im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> (see also the "Availability of Companion Documents" field).</p></div></p>
<h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
<p><div class="content_para"><p><strong><span style="text-decoration: underline;">Appropriateness Category Names and Definitions</span></strong></p>
<table border="1" cellspacing="1" cellpadding="5" summary="Table: Appropriateness Category Names and Definitions">
<thead>
<tr>
<th class="Center" valign="top" scope="col">Appropriateness Category Name</th>
<th class="Center" valign="top" scope="col">Appropriateness Rating</th>
<th class="Center" valign="top" scope="col">Appropriateness Category Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td class="Center" valign="top">Usually Appropriate</td>
<td class="Center" valign="top">7, 8, or 9</td>
<td valign="top">The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.</td>
</tr>
<tr>
<td class="Center" valign="top">May Be Appropriate</td>
<td class="Center" valign="top">4, 5, or 6</td>
<td valign="top">The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.</td>
</tr>
<tr>
<td class="Center" valign="top">May Be Appropriate (Disagreement)</td>
<td class="Center" valign="top">5</td>
<td valign="top">The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel's recommendation. "May be appropriate" is the rating category and a rating of 5 is assigned.</td>
</tr>
<tr>
<td class="Center" valign="top">Usually Not Appropriate</td>
<td class="Center" valign="top">1, 2, or 3</td>
<td valign="top">The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.</td>
</tr>
</tbody>
</table></div></p>
<h3><a href="#">Cost Analysis</a></h3>
<p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
<h3><a href="#">Method of Guideline Validation</a></h3>
<p>Internal Peer Review</p>
<h3><a href="#">Description of Method of Guideline Validation</a></h3>
<p><div class="content_para"><p>Criteria developed by the Expert Panels are reviewed by the American College of Radiology (ACR) Committee on Appropriateness Criteria.</p></div></p>
</div>
<h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
<p><div class="content_para"><p>The recommendations are based on analysis of the current medical evidence literature and the application of the RAND/UCLA appropriateness method and expert panel consensus.</p>
<p><strong><span style="text-decoration: underline;">Summary of Evidence</span></strong> </p>
<p>Of the 100 references cited in the <em>ACR Appropriateness Criteria® Abdominal Aortic Aneurysm: Interventional Planning and Follow-up</em> document, 16 are categorized as therapeutic references, including 5 well-designed studies, 8 good-quality studies. Additionally, 80 references are categorized as diagnostic references including 4 well-designed studies, 15 good-quality studies, and 30 quality studies that may have design limitations. There are 34 references that may not be useful as primary evidence. There are 4 references that are meta-analysis studies. </p>
<p>Although there are references that report on studies with design limitations, 32 well-designed or good-quality studies provide good evidence.</p></div></p>
</div>
<h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Potential Benefits</a></h3>
<p><ul style="list-style-type: disc;">
<li>Patients intolerant of gadolinium-based contrast media (GBCM) or those at risk for nephrogenic systemic fibrosis (NSF) may benefit from the acquisition of noncontrast balanced steady state free precession (bSSFP) images in post-endovascular repair (EVAR) surveillance. </li>
<li>Blood pool contrast materials such as ferumoxytol remain intravascular for a prolonged duration, thereby allowing for generation of high-resolution 3-D multiplanar images. Use of these contrast materials may improve detection of slow-flow endoleaks. </li>
<li>The ultimate goal of endovascular therapy is to prevent aneurysm rupture. Follow-up imaging is the most useful tool for evaluating post-therapeutic outcomes and monitoring potential complications. Successful therapy results in an aneurysm that remains stable or decreases in size over serial follow-up imaging examinations, with decreasing size of the aneurysm sac believed to indicate a low risk of future rupture. </li>
</ul></p>
<h3><a href="#">Potential Harms</a></h3>
<p><ul style="list-style-type: disc;">
<li>A disadvantage of computed tomography angiography (CTA) includes potential nephrotoxicity from administered contrast material. </li>
<li>Disadvantages of magnetic resonance angiography (MRA) include relatively long scanning duration, patient claustrophobia, decreased spatial resolution, and contraindication in patients with certain implantable devices. MRA is also limited in its ability to detect intimal calcification. Additionally, susceptibility artifact from the metal interstices of the stent graft presents a diagnostic challenge for assessing device integrity and may mimic graft stenosis. </li>
</ul>
<p><span style="text-decoration: underline;"><strong>Relative Radiation Level Information</strong></span></p>
<p>Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults. Additional information regarding radiation dose assessment for imaging examinations can be found in the American College of Radiology (ACR) Appropriateness Criteria® Radiation Dose Assessment Introduction document (see the "Availability of Companion Documents" field).</p></p>
</div>
<h2 id="430" class="accordion-title section-430 is-active" role="tab" aria-expanded="true"><a href="#">Contraindications</a></h2>
<div class="accordion-panel is-active" role="tabpanel">
<h3><a href="#">Contraindications</a></h3>
<p><ul style="list-style-type: disc;">
<li>Although not an absolute contraindication to endovascular aneurysm repair (EVAR), mural thrombus and atherosclerotic calcification covering more than 90° of the circumference of the aortic diameter in the proximal neck is associated with a higher risk for type I endoleak and stent-graft migration. </li>
<li>Magnetic resonance angiography (MRA) is contraindicated in patients with certain implantable devices. Although the presence of an implanted cardiac pacemaker was previously an absolute contraindication to magnetic resonance imaging (MRI), several new models are U.S. Food and Drug Administration (FDA)-approved for conditional use.</li>
<li>Severe renal impairment and life-threatening contrast allergy are contraindications to iodinated contrast. </li>
</ul></p>